GC1118

recombinant human anti-EGFR antibody · Green Cross Corporation

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for GC1118, covering 2016-07-06 to 2023-05-12. Get the full timeline:

Most recent: Clinical Trial Update: GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification [Phase 2]